Apixaban Shows Superior Safety Profile Over Rivaroxaban in Major Venous Thromboembolism Trial
Key Insights
The COBRRA trial found that apixaban reduced bleeding risk by more than half compared to rivaroxaban in 2,760 patients with acute venous thromboembolism (search) over three months.
Clinically relevant bleeding occurred in 3.3% of apixaban patients versus 7.1% of rivaroxaban patients, with no significant difference in blood clot recurrence rates.
Despite higher medication adherence with rivaroxaban (75.1% vs 65.7%), the safety advantage of apixaban remained consistent across the international study.
The first head-to-head clinical trial comparing two widely prescribed anticoagulants for venous thromboembolism (search) has demonstrated that apixaban significantly reduces bleeding risk compared to rivaroxaban while maintaining similar efficacy in preventing blood clot recurrence. The landmark COBRRA trial results, published in The New England Journal of Medicine, could reshape treatment guidelines for the third leading cause of cardiovascular death.
Trial Design and Patient Population
The prospective, randomized, open-label, masked endpoint COBRRA trial enrolled 2,760 patients with acute symptomatic pulmonary embolism (search) or proximal deep vein thrombosis (search) across 32 sites in Canada, Australia, and Ireland. Participants had a mean age of 58 years, with most being men and white.
Patients were randomly assigned to receive either apixaban (10 mg twice daily for 7 days, then 5 mg twice daily for 3 months) or rivaroxaban (15 mg twice daily for 21 days, then 20 mg daily for 3 months). The primary outcome measured clinically relevant bleeding, defined as a composite of major bleeding or clinically relevant nonmajor bleeding.
Significant Safety Advantage for Apixaban
The trial revealed a striking difference in bleeding risk between the two treatments. Clinically relevant bleeding occurred in 3.3% of patients receiving apixaban compared to 7.1% of those receiving rivaroxaban, representing a relative risk ratio of 0.46 favoring apixaban (95% CI, 0.33-0.65; P < .001).
"Results showed that 7.1 per cent of participants who received rivaroxaban experienced clinically relevant bleeding after three months compared to 3.3 per cent of participants who received apixaban, representing more than double the risk of bleeding with rivaroxaban," the researchers reported.
Efficacy Remains Comparable
Despite the safety differences, both medications demonstrated similar effectiveness in preventing recurrent venous thromboembolism (search). The percentage of patients with recurrent blood clots during the 3-month trial period was approximately 1% in each group. All-cause death occurred in 0.1% of the apixaban group and 0.3% of the rivaroxaban group (RR = 0.25; 95% CI, 0.03-2.26), with no deaths due to recurrent VTE in either treatment group.
Adherence Patterns and Clinical Implications
Interestingly, medication adherence was higher in the rivaroxaban group, with 75.1% of patients reporting full adherence compared to 65.7% in the apixaban group. Serious adverse events unrelated to bleeding or venous thrombosis (search) occurred in 2.7% of the apixaban group and 2.2% of the rivaroxaban group.
Lead author Dr. Lana Castellucci, associate professor at Ottawa Hospital Research Institute, noted that the trial "does not explain the difference in bleeding risk between patients treated with apixaban and those treated with rivaroxaban." However, she suggested that "the difference in the risk of clinically relevant bleeding may be related to the dose of rivaroxaban, given that most of the difference seems to have occurred during the first 3 weeks of treatment, a period when rivaroxaban was given at a dose that was 50% higher than the maintenance dose."
Practice-Changing Implications
Dr. Castellucci emphasized the clinical significance of these findings: "These results clearly show that apixaban is the safer option for treating venous thrombosis (search). This trial provides highly anticipated evidence for physicians and should bring real peace of mind to venous thrombosis patients, who often live with the dual fear of blood clot recurrence and bleeding."
Senior author Dr. Marc Rodger, Physician-in-Chief at the McGill University Health Centre, described the study as "practice-changing" and highlighted its impact on evidence-based medicine.
The international scope of the trial strengthens its clinical relevance. Dr. Vivien Chen, Thrombosis Lead Haematologist at Concord Hospital (search) and professor at University of Sydney, noted: "Because this was a real world, standard of care trial conducted across three countries, the findings have strong global relevance. Patients in Australia, Canada and Ireland were treated according to routine clinical practice, making the findings broadly applicable to diverse health systems and patient populations."
Current Treatment Landscape
Venous thrombosis (search) represents a significant clinical challenge as the most common preventable cause of death in hospitalized patients. Current clinical practice guidelines do not recommend one direct oral anticoagulant over another due to the previous lack of head-to-head trials comparing bleeding risks between rivaroxaban and apixaban.
The COBRRA trial addresses this critical evidence gap, providing clinicians with data to guide treatment decisions for the thousands of patients diagnosed with venous thromboembolism (search) annually. The researchers noted that further evaluation in clinical trials is needed to confirm whether the rivaroxaban dosing regimen contributed to the observed bleeding risks.